Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
GLP-1 SM is the coded designation for a research peptide studied as a long-acting GLP-1 receptor agonist, one of several incretin-class compounds that laboratories investigate as tools for probing metabolic signaling. Among the GLP peptides for sale as research materials, it is the single-receptor member of a family that also includes the dual and triple incretin agonists and the amylin analog Cagrilintide. This article is an orientation to what GLP-1 SM is: how it is classified, what receptor it engages, how it differs from its sibling compounds, and what quality documentation matters when a laboratory sources it.
The intent here is descriptive rather than instructional. GLP-1 SM is characterized by its sequence, molecular weight, and receptor selectivity, and it is studied only in preclinical, in-vitro, and animal-model settings. Nothing below concerns clinical application; all material is provided for research use only, not for human consumption. Researchers comparing incretin compounds can view the full range on the research peptides catalog.
What GLP-1 SM Is
A Synthetic Incretin Analog
GLP-1 SM is a synthetic peptide modeled on the active fragment of native glucagon-like peptide-1, an incretin hormone produced by intestinal L-cells. Native GLP-1 is short-lived because the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it within minutes. GLP-1 SM belongs to the category of engineered analogs that carry structural changes reported to slow that breakdown and extend the peptide’s presence in laboratory buffers and animal models, which is why it is described as a long-acting agonist rather than a copy of the natural hormone.
Identity at a Glance
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Designation | GLP-1 SM |
| Compound class | GLP-1 receptor agonist (incretin mimetic peptide) |
| Parent peptide | Glucagon-like peptide-1 (GLP-1) |
| Sequence length | About 31 amino acids |
| Approximate molecular weight | Roughly 4114 g/mol (about 4.1 kDa) |
| Primary molecular target | GLP-1 receptor (GLP-1R) |
| Receptor family | Class B (secretin-like) GPCR |
| Principal second messenger | Cyclic AMP (cAMP) |
| Stability strategy | Structural modification studied for DPP-4 resistance and albumin binding |
Because the same coded designation can be attached to material of varying quality, the identity attributes above are only meaningful when confirmed for a given lot. A supplier’s certificate of analysis reports the measured mass and purity that should match this profile before a peptide enters an experiment.
The GLP-1 Receptor It Targets
A Class B GPCR
The defining feature of GLP-1 SM is its target, the GLP-1 receptor, a class B (secretin-like) G-protein-coupled receptor expressed on pancreatic islet cells and mapped in the central nervous system, heart, kidney, and gastrointestinal tract of animal models. Class B GPCRs use a large extracellular domain to capture the C-terminal portion of a peptide ligand, followed by a seven-transmembrane bundle that changes conformation on binding. Cryo-EM structures of the GLP-1 receptor bound to agonists, first resolved by the Sexton and Wootten groups, gave the field a detailed picture of how a peptide of this size docks into the receptor.
Downstream Signaling
Classically, an activated GLP-1 receptor couples to the stimulatory Gs protein and raises intracellular cyclic AMP (cAMP), which recruits protein kinase A and the exchange factor Epac2. Recent work has refined that picture. A 2026 Nature Metabolism study of GLP-1R-expressing neurons in the hindbrain area postrema reported that agonist signaling engages both Gs- and Gq-dependent pathways and produces graded cAMP responses, with phosphodiesterase-4 inhibition sustaining the cAMP signal. In parallel, review literature through 2025 and 2026 has catalogued GLP-1 receptor signaling in neural models through the cAMP/PKA/CREB and PI3K/Akt cascades. These are the pathways GLP-1 SM is used to probe in the laboratory.
GLP-1 SM Among the GLP Research Peptides
GLP-1 SM is best understood next to the related incretin compounds it is often catalogued with. The GLP family differs mainly in how many receptors each member engages, which is the single most useful axis for telling them apart. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Research peptide | Receptor targets | Agonism class | Approx. MW | Approx. length |
|---|---|---|---|---|
| GLP-1 SM | GLP-1R | Single-receptor agonist | ~4114 Da | ~31 aa |
| GLP-2 TZ | GIPR, GLP-1R | Dual-receptor agonist | ~4813 Da | ~39 aa |
| GLP-3 RT | GLP-1R, GIPR, GCGR | Triple-receptor agonist | ~4731 Da | ~39 aa |
| Cagrilintide | Amylin and calcitonin receptors | Amylin analog | ~3750 Da | ~37 aa |
GLP-1 SM anchors the low end of this range as the single-receptor agonist. Its mechanism is the subject of a companion article on GLP-1 SM signal transduction, and its place in the wider category is covered in the metabolic research peptides overview. Because the coded designations map to distinct sequences and receptor profiles, choosing among them in a research setting is a question of which signaling pathways a study is designed to interrogate, not of relative potency claims.
Sourcing GLP Peptides for Sale as Research Material
What to Verify Before Buying
For researchers evaluating GLP peptides for sale, the decisive variables are identity, purity, and documentation rather than the label alone. A credible listing is backed by a lot-specific certificate of analysis showing HPLC purity (commonly 98 percent or higher for research-grade peptide) and mass spectrometry confirmation that the measured molecular weight matches the expected value. The guide on choosing a research peptide supplier lays out the full checklist, and published certificates of analysis let a stated profile be checked against the actual material.
Handling and Storage
GLP-1 SM is supplied as a lyophilized powder. It is stored cold and reconstituted for use with bacteriostatic water, a step whose arithmetic and stability factors are covered in the reconstitution guide. Like other acylated and structurally modified peptides, it is sensitive to repeated freeze-thaw cycles and to prolonged time at room temperature, so aliquoting and cold storage preserve integrity across an experiment.
In summary, GLP-1 SM is the single-receptor GLP-1 receptor agonist within a small family of incretin research peptides, defined by a roughly 31-residue sequence, a molecular weight near 4114 g/mol, and a class B GPCR target that signals through cAMP. Whether it is evaluated on its own or alongside the other GLP peptides for sale as research compounds, it remains a laboratory material supplied for research use only, not for human consumption, and its value in any study depends on verified identity and careful handling.
Frequently Asked Questions
What is GLP-1 SM?
GLP-1 SM is the coded designation for a research peptide studied as a long-acting GLP-1 receptor agonist. It is a synthetic analog of native glucagon-like peptide-1, modified to resist enzymatic breakdown, and it is investigated only in preclinical and in-vitro settings as a tool for studying incretin-receptor signaling.
What does GLP-1 receptor agonist mean?
A GLP-1 receptor agonist is a molecule that binds and activates the GLP-1 receptor, a class B G-protein-coupled receptor. Activation classically raises intracellular cyclic AMP and engages the PKA and Epac2 signaling pathways, the cascades that GLP-1 SM is used to probe in laboratory models.
Where can researchers find GLP-1 research peptides for study?
Research-grade GLP peptides are catalogued by suppliers that publish lot-specific certificates of analysis. When evaluating GLP-1 research peptides and where to buy them, the reliable signals are HPLC purity data, mass spectrometry identity confirmation, and clear research-use-only labeling, all of which should accompany the listing.
How is GLP-1 SM different from GLP-2 TZ and GLP-3 RT?
The difference is receptor coverage. GLP-1 SM is a single-receptor agonist acting at the GLP-1 receptor, GLP-2 TZ is a dual agonist adding the GIP receptor, and GLP-3 RT is a triple agonist adding the glucagon receptor. They also differ in sequence length and molecular weight, as the comparison table shows.
What should a certificate of analysis for GLP-1 SM show?
A certificate of analysis should report HPLC purity, a mass spectrometry result confirming the molecular weight near 4114 g/mol, and lot-specific identification. Matching the measured mass to the expected value is how a laboratory confirms that the coded designation corresponds to the intended sequence.
Is GLP-1 SM intended for human use?
No. GLP-1 SM is a research compound offered for laboratory investigation only. It is not a medicine and is supplied strictly for research use only, not for human consumption, self-administration, or therapeutic use.
References and Further Reading
- Gao C and colleagues, Nature Metabolism, 2026, on cAMP-dependent signaling in GLP-1 receptor-expressing hindbrain neurons of the area postrema. PubMed: GLP-1 receptor hindbrain area postrema cAMP
- Li P, Gao Y, Liu W, Drug Design, Development and Therapy, 2026, reviewing GLP-1 receptor agonist mechanisms across neurological models, including cAMP/PKA/CREB and PI3K/Akt pathways. PubMed: GLP-1 receptor agonist neurological mechanisms review
- Roy A, Dawson VL, Dawson TM, Neurotherapeutics, 2025, on the expanding role of the GLP-1 receptor from metabolism to neural signaling. PubMed: GLP-1 receptor metabolism to mind neurotherapeutics
- Cryo-EM structural studies of the GLP-1 receptor bound to peptide agonists (Sexton, Wootten, and colleagues) describing class B GPCR activation. PubMed: GLP-1 receptor cryo-EM agonist structure
- Studies of DPP-4 resistance and albumin-binding strategies used to extend the stability of GLP-1 receptor agonist analogs. PubMed: GLP-1 analog DPP-4 resistance albumin binding
- Research on GLP-1 receptor signaling in pancreatic islet and beta-cell models, including glucose-dependent cAMP responses. PubMed: GLP-1 receptor islet beta cell cAMP glucose
- Generation and characterization of a humanized GLP-1 receptor mouse model for preclinical study of GLP-1 receptor agonists, EBioMedicine, 2026. PubMed: humanized GLP-1 receptor mouse model
